Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML61S4)

• Drug Name: ARQ-151 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Phase 3	[1]
Psoriasis vulgaris	EA90	Phase 2	[2]
Plaque psoriasis	EA90.0	Phase 1/2	[3]

• Cross-matching ID:
  PubChem CID: 449193
  TTD Drug ID: DML61S4

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 4 (PDE4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[5]
Oxtriphylline	DMLHSE3	Cough	MD12	Approved	[6]
Roflumilast	DMPGHY8	Asthma	CA23	Approved	[7]
Ibudilast	DM4LSPN	Castleman's disease	4B2Y	Approved	[8]
crisaborole	DMNVKU6	Atopic dermatitis	EA80	Approved	[9]
Arofylline	DM84AD1	Chronic obstructive pulmonary disease	CA22	Phase 3	[10]
SUN13834	DMPK34E	Gram-positive bacterial infection	1B74-1G40	Phase 2	[11]
ONO-6126	DMRT28X	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
E6005	DM1S489	Atopic dermatitis	EA80	Phase 2	[12]
IC-485	DMB1UYV	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 4 (PDE4)	TTV5CGO	NOUNIPROTAC	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT04804605) Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04746911) Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
• [5] Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [8] Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
• [9] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [10] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [11] Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
• [12] Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.